Effect of the pyridoindole SME1EC2 and compounds affecting A1 andA2A adenosine receptors in rat hippocampus under ischemia in vitro

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 353-360

  Gáspárová, Zdenka ^a   Jariabka, Pavol ^a   Štolc, Svorad ^a  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Adenosine; Hippocampus; Ischemia; Pyridoindoles; Synaptic transmission

Indexed keywords

2 ETHOXYCARBONYL 8 METHOXY 2,3,4,4A,5,9B HEXAHYDRO 1H PYRIDO[4,3B]INDOLINIUM CHLORIDE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; CARBOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN SLICE; CONTROLLED STUDY; HIPPOCAMPUS; IN VITRO STUDY; MALE; NERVE EXCITABILITY; NEUROPROTECTION; NONHUMAN; RAT; REOXYGENATION; SYNAPTIC TRANSMISSION;

EID: 49349103719     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Canhao P, de Mendonca A, Ribeiro JA: 1,3-Dipropy1-8-cyclopentylxanthine attenuates the NMDA response to hypoxia in the rat hippocampus. Brain Res, 1994, 661, 265-273.
2. Cassar M, Jones MG, Szatkowski M: Reduced adenosine uptake accelerates block of population spikes in hippocampal slices from streptozotocin-treated diabetic rats. Eur J Neurosci, 1998, 10, 239-245.
3. Choi BH: Oxygen, antioxidants and brain dysfunction. Yonsei Mod J, 1993, 34, 1-10.
4. Gáspárovi Z, Štolc S, Šnirc V: In vitro physiological evidence of enhanced neuroprotective and antioxidant action of 2,3-dihydromelatonin: a melatonin analogue. Pharmacol Res, 2006, 53, 22-27.
5. Gilbert ME, Burdette LJ: Hippocampal field potentials: a model system to characterize neurotoxicity. In: Neurotoxicology: Approaches and Methods. Ed. Chang LW, Slikker W, Academic Press, San Diego, 1995, 183-204.
6. Hochachka PW: ATP supply and demand. In: Tissue Oxygen Deprivation. Ed. Haddad GG, Lister G, Marcel Dekker, New York, 1996, 51-80.
7. Kvaltínová Z, Štolc S: NMDA binding sites in rat hippocampus under oxidative stress: Effect of antioxidants and NMDA antagonists. Ann NY Acad Sci, 1997, 812, 240-242.
8. 2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischaemia in rat hippocampal slices. Br J Pharmacol, 1999, 128, 1035-1044.
9. Li X, Eisenach JC: Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology, 2005, 103, 1060-1065.
10. Liniger R, Popovic R, Sulliva B, Gregory G, Bickler PE: Effects of neuraprotective cocktails on hippocampal neuron death in an in vitro model of cerebral ischemia. J Neurosurg Anesthesiol, 2001, 13, 19-25.
11. Masino SA, Mesches MH, Bickford PC, Dunwidie TV: Acute peroxide treatment of rat hippocampal slices induces adenosine-mediated inhibition of excitatory transmission in area CA1. Neurosci Lett, 1999, 274, 91-94.
12. Pearson T, Currie AJ, Etherington LAV, Gadalla AE, Damian K, Llaudet E, Date N et al.: Plasticity of purine release during cerebral ischemia: clinical implication? J Cell Mol Med, 2003, 7, 362-375.
13. Pearson T, Damian K, Lynas RE, Frenguelli BG: Sustained elevation of extracellular adenosine and activation of A1 receptors underlie the post-ischaemic inhibition of neuronal function in rat hippocampus in vitro. J Neurochem, 2006, 97, 1357-1368.
14. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB: Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev, 1992, 4, 346-369.
15. Saransaari P, Oja SS: Mechanisms of adenosine release in the developing and adult mouse hippocampus. Neurochem Res, 2002, 27, 911-918.
16. Schubert P, Ogata T, Marchini C, Ferroni S, Rudolphi K: Protective mechanisms of adenosine in neurons and glial cells. Ann NY Acad Sci, 1997, 825, 1-10.
17. Schubert P, Rudolphi KA, Fredholm BB, Nakmura Y: Modulation of nerve and glial function by adenosine role in the development of ischemia damage. Int J Biochem, 1994, 26, 1227-1236.
18. Štolc S, Bauer V, Beneg L, Tichý M. Patents: CS 229067, SCHWED. 8204693-9, BELG. 894148, SWISS 651754, BRD P-3231088, SPAIN 553017, JAP 1514040; 1983.
19. Štolc S, Považanec F, Bauer V, Májeková M, Wilcox AL, Šnirc V, Račková L et al.: Pyridoindole derivatives with antioxidant properties, their synthesis and use in clinical practice. Slovak Patent Pending PP 1321-2003 (Slovak), 2003.
20. Štolc S, Selecká J: Protective effect of stobadine, a pyridoindole antioxidant, in hypoxia-reoxygenation injury of ganglionic and hippocampal neurotransmission. Mol Chem Neuropathol, 1995, 25, 199-212.
21. Štolc S, Šnirc V, Májeková M, Gáspárová Z, Gajdošiková A, Štvrtina S: Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress. Cell Mol Neurobiol, 2006, 26, 1493-1502.
22. Taylor JM, Crack PJ: Impact of oxidative stress on neuronal survival. Clin Exp Pharmacol Physiol, 2004, 31, 397-406.
23. Vlkolinský R, Štolc S: Effects of stobadine, melatonin, and other antioxidants on hypoxia/reoxygenation-induced synaptic transmission failure in rat hippocampal slices. Brain Res, 1999, 850, 118-126.
24. Von Lubitz DK: Adenosine treatment of stroke: yes, maybe, or absolutely not? Expert Opin Investig Drugs, 2001, 10, 619-632.
25. 3 receptors and cerebroprotection in stroke? Ann NY Acad Sci, 2001, 939, 85-96.